Nektar Therapeutics
$100.35
▲
1.69%
2026-04-21 08:25:01
www.nektar.com
NCM: NKTR
Explore Nektar Therapeutics stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.87 B
Current Price
$100.35
52W High / Low
$109 / $7.99
Stock P/E
—
Book Value
$4.41
Dividend Yield
—
ROCE
-57.64%
ROE
-2.18%
Face Value
—
EPS
$-9.73
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
63
Beta
1.18
Debt / Equity
165.76
Current Ratio
4.97
Quick Ratio
4.97
Forward P/E
-6.9
Price / Sales
40.25
Enterprise Value
$2.13 B
EV / EBITDA
-16.39
EV / Revenue
38.5
Rating
Strong Buy
Target Price
$128.12
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Corvus Pharmaceuticals, Inc. | $15.54 | — | $1.31 B | — | -69.6% | -32.6% | $26.95 / $3.11 | $0.82 |
| 2. | eXoZymes, Inc. | $10.66 | — | $89.88 M | — | -220.6% | -1.33% | $18.4 / $7.08 | $0.4 |
| 3. | Coeptis Therapeutics Holdings, Inc. | $15.54 | — | $91.17 M | — | -90.67% | -1.37% | $21.41 / $6.26 | $2.36 |
| 4. | Kyntra Bio, Inc. | $7.34 | 0.16 | $29.62 M | — | -50.18% | -143.52% | $12.6 / $4.85 | $-7.42 |
| 5. | Virax Biolabs Group Limited | $0.14 | — | $1.05 M | — | -107.11% | -83.82% | $1.2 / $0.1 | $0.81 |
| 6. | Arvinas, Inc. | $10.81 | — | $703.57 M | — | -20.59% | -16.23% | $14.51 / $5.9 | $6.83 |
| 7. | Mineralys Therapeutics, Inc. | $30.07 | — | $2.52 B | — | -26.38% | -36.91% | $47.65 / $12.59 | $7.93 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 21.81 M | 11.79 M | 11.18 M | 10.46 M | 29.18 M | — |
| Operating Profit | -19.09 M | -31.53 M | -35.78 M | -44.37 M | -24.68 M | — |
| Net Profit | -36.08 M | -35.52 M | -41.59 M | -50.88 M | 7.26 M | — |
| EPS in Rs | -1.26 | -1.24 | -1.45 | -1.77 | 0.25 | 2.66 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 55.23 M | 98.43 M | 90.12 M | 92.06 M |
| Operating Profit | -130.77 M | -129.92 M | -135.22 M | -240.24 M |
| Net Profit | -164.08 M | -118.96 M | -276.06 M | -368.2 M |
| EPS in Rs | -5.72 | -4.15 | -9.62 | -12.83 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 280.41 M | 303.85 M | 398.03 M | 710.6 M |
| Total Liabilities | 190.57 M | 243.11 M | 267.05 M | 343.96 M |
| Equity | 89.83 M | 60.74 M | 130.99 M | 366.64 M |
| Current Assets | 266.27 M | 261.29 M | 330.7 M | 545.97 M |
| Current Liabilities | 53.54 M | 61.4 M | 51.27 M | 68.2 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -208.51 M | -175.71 M | -192.61 M | -304.01 M |
| Investing CF | -1.2 M | 142.57 M | 139.56 M | 365.83 M |
| Financing CF | 180.57 M | 42.12 M | 0.03 M | 1.51 M |
| Free CF | -208.68 M | -177.18 M | -193.47 M | -309.68 M |
| Capex | -0.17 M | -1.47 M | -0.86 M | -5.68 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 9.22% | -2.1% | — | — |
| Earnings Growth % | 56.91% | 25.03% | — | — |
| Profit Margin % | -120.86% | -306.31% | -399.98% | — |
| Operating Margin % | -131.99% | -150.05% | -260.97% | — |
| Gross Margin % | 68.82% | 62.53% | 76.5% | — |
| EBITDA Margin % | -88.08% | -269.75% | -350.92% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-06-09 | 1:0.0666667 |